交易 Calcimedica Inc - CALC CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | 0.6864 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.024068% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.001846% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 0.001 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
Mar 22, 2023 | 5.5768 | 0.2301 | 4.30% | 5.3467 | 6.5507 | 5.0805 |
Mar 21, 2023 | 6.0468 | 1.2311 | 25.56% | 4.8157 | 6.1436 | 4.7284 |
Mar 20, 2023 | 5.3451 | -0.6469 | -10.80% | 5.9920 | 5.9920 | 5.0602 |
Mar 17, 2023 | 0.4280 | -0.0478 | -10.05% | 0.4758 | 0.4763 | 0.4273 |
Mar 16, 2023 | 0.4761 | -0.0195 | -3.93% | 0.4956 | 0.4958 | 0.4580 |
Mar 15, 2023 | 0.4937 | 0.0277 | 5.94% | 0.4660 | 0.4969 | 0.4660 |
Mar 14, 2023 | 0.4762 | -0.0145 | -2.95% | 0.4907 | 0.4957 | 0.4737 |
Mar 13, 2023 | 0.4960 | -0.0093 | -1.84% | 0.5053 | 0.5151 | 0.4859 |
Mar 10, 2023 | 0.5041 | 0.0008 | 0.16% | 0.5033 | 0.5120 | 0.4857 |
Mar 9, 2023 | 0.5346 | -0.0034 | -0.63% | 0.5380 | 0.5637 | 0.5164 |
Mar 8, 2023 | 0.5638 | 0.0408 | 7.80% | 0.5230 | 0.5647 | 0.5230 |
Mar 7, 2023 | 0.5637 | 0.0395 | 7.54% | 0.5242 | 0.5823 | 0.5242 |
Mar 6, 2023 | 0.5556 | -0.0273 | -4.68% | 0.5829 | 0.5829 | 0.5537 |
Mar 3, 2023 | 0.5476 | 0.0429 | 8.50% | 0.5047 | 0.5588 | 0.5047 |
Mar 2, 2023 | 0.5345 | 0.0292 | 5.78% | 0.5053 | 0.5347 | 0.5053 |
Mar 1, 2023 | 0.5390 | 0.0045 | 0.84% | 0.5345 | 0.5832 | 0.5339 |
Feb 28, 2023 | 0.5285 | -0.0056 | -1.05% | 0.5341 | 0.5347 | 0.5179 |
Feb 27, 2023 | 0.5536 | -0.0004 | -0.07% | 0.5540 | 0.5543 | 0.5343 |
Feb 24, 2023 | 0.5439 | -0.0390 | -6.69% | 0.5829 | 0.5975 | 0.5273 |
Feb 23, 2023 | 0.5915 | 0.0065 | 1.11% | 0.5850 | 0.6124 | 0.5837 |
Calcimedica Inc Events
時間(協調世界時) (UTC) | 國家 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 |
总营业费用 | 35.947 | 29.832 | 37.502 | 28.57 |
销售/一般/行政费用,总计 | 17.044 | 8.87 | 6.922 | 5.599 |
研究与开发 | 18.903 | 20.962 | 30.58 | 22.971 |
营业收入 | -35.947 | -29.832 | -37.502 | -28.57 |
利息收入(费用),非经营净值 | 0.126 | 0.143 | 0.393 | 0.192 |
其他,净值 | 0 | 2.158 | 0.072 | 0 |
税前净收入 | -35.821 | -27.531 | -37.037 | -28.378 |
税后净收入 | -35.821 | -27.531 | -37.037 | -28.378 |
未计算非常项目前的净收益 | -35.821 | -27.531 | -37.037 | -28.378 |
净收入 | -35.821 | -27.531 | -37.037 | -28.378 |
Total Adjustments to Net Income | 0 | -7.189 | -7.055 | -4.317 |
普通股股东可获收益 (不含非经常性项目) | -35.821 | -34.72 | -44.092 | -32.695 |
普通股股东可获收益 (含非經常性項目) | -35.821 | -34.72 | -44.092 | -32.695 |
摊薄净收入 | -35.821 | -34.72 | -44.092 | -32.695 |
摊薄后加权平均股 | 21.1993 | 21.044 | 19.1556 | 19.1556 |
扣除特别项目的每股摊薄盈利 | -1.68973 | -1.64988 | -2.30178 | -1.70681 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
每股正常摊薄盈利 | -1.68973 | -1.64988 | -2.30178 | -1.70681 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 10.184 | 8.701 | 8.017 | 7.741 | 11.488 |
销售/一般/行政费用,总计 | 4.127 | 4.433 | 3.996 | 3.575 | 5.04 |
研究与开发 | 6.057 | 4.268 | 4.021 | 4.166 | 6.448 |
营业收入 | -10.184 | -8.701 | -8.017 | -7.741 | -11.488 |
利息收入(费用),非经营净值 | 0.035 | 0.026 | 0.028 | 0.033 | 0.039 |
其他,净值 | 0 | 0 | 0 | 0 | |
税前净收入 | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
税后净收入 | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
未计算非常项目前的净收益 | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
净收入 | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
普通股股东可获收益 (不含非经常性项目) | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
普通股股东可获收益 (含非經常性項目) | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
摊薄净收入 | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
摊薄后加权平均股 | 21.3578 | 21.3376 | 21.2875 | 21.1487 | 21.0204 |
扣除特别项目的每股摊薄盈利 | -0.47519 | -0.40656 | -0.37529 | -0.36447 | -0.54466 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.47519 | -0.40656 | -0.37529 | -0.36447 | -0.54466 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
流动资产总额 | 67.078 | 99.24 | 36.271 | 13.445 |
现金和短期投资 | 63.67 | 95.033 | 35.956 | 12.834 |
现金等价物 | 13.364 | 33.418 | 15.87 | 12.834 |
短期投资 | 50.306 | 61.615 | 20.086 | 0 |
Prepaid Expenses | 2.034 | 4.207 | 0.315 | 0.611 |
Total Assets | 69.088 | 101.794 | 40.66 | 17.813 |
Property/Plant/Equipment, Total - Net | 1.981 | 1.946 | 1.975 | 1.515 |
Property/Plant/Equipment, Total - Gross | 3.634 | 3.08 | 2.714 | 1.958 |
Accumulated Depreciation, Total | -1.653 | -1.134 | -0.739 | -0.443 |
Other Long Term Assets, Total | 0.029 | 0.608 | 2.414 | 2.853 |
Total Current Liabilities | 4.057 | 6.997 | 12.251 | 5.794 |
Accounts Payable | 0.527 | 2.513 | 4.636 | 2.523 |
Accrued Expenses | 2.582 | 3.658 | 4.377 | 2.924 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.948 | 0.826 | 3.238 | 0.347 |
Total Liabilities | 4.065 | 7.008 | 12.251 | 5.794 |
Total Long Term Debt | 0 | 0 | 0 | 0 |
Total Equity | 65.023 | 94.786 | 28.409 | 12.019 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 131.363 | 78.811 |
Common Stock | 0.002 | 0.002 | 0 | 0 |
Additional Paid-In Capital | 234.225 | 228.155 | 2.879 | 2.007 |
Retained Earnings (Accumulated Deficit) | -169.188 | -133.367 | -105.836 | -68.799 |
Unrealized Gain (Loss) | -0.016 | -0.004 | 0.003 | 0 |
Total Liabilities & Shareholders’ Equity | 69.088 | 101.794 | 40.66 | 17.813 |
Total Common Shares Outstanding | 21.3578 | 20.9793 | 19.1556 | 19.1556 |
Other Liabilities, Total | 0.008 | 0.011 | ||
Total Preferred Shares Outstanding | 0 | |||
应收账款总额,净额 | 0.021 | |||
Other Current Assets, Total | 1.353 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
流动资产总额 | 58.222 | 67.078 | 74.496 | 76.051 | 88.821 |
现金和短期投资 | 55.28 | 63.67 | 72.554 | 73.586 | 85.688 |
现金等价物 | 8.36 | 13.364 | 11.452 | 7.864 | 10.589 |
短期投资 | 46.92 | 50.306 | 61.102 | 65.722 | 75.099 |
Prepaid Expenses | 2.942 | 3.408 | 1.942 | 2.465 | 3.133 |
Total Assets | 60.586 | 69.088 | 76.638 | 82.821 | 90.852 |
Property/Plant/Equipment, Total - Net | 2.335 | 1.981 | 2.113 | 2.006 | 2.002 |
Other Long Term Assets, Total | 0.029 | 0.029 | 0.029 | 0.136 | 0.029 |
Total Current Liabilities | 4.228 | 4.057 | 4.49 | 4.141 | 6.278 |
Accounts Payable | 0.541 | 0.527 | 2.066 | 2.101 | 1.956 |
Accrued Expenses | 2.216 | 2.582 | 1.729 | 1.543 | 3.378 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.471 | 0.948 | 0.695 | 0.497 | 0.944 |
Total Liabilities | 4.33 | 4.065 | 4.502 | 4.154 | 6.29 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.102 | 0.008 | 0.012 | 0.013 | 0.012 |
Total Equity | 56.256 | 65.023 | 72.136 | 78.667 | 84.562 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 235.767 | 234.225 | 232.641 | 231.183 | 229.376 |
Retained Earnings (Accumulated Deficit) | -179.337 | -169.188 | -160.513 | -152.524 | -144.816 |
Unrealized Gain (Loss) | -0.176 | -0.016 | 0.006 | 0.006 | 0 |
Total Liabilities & Shareholders’ Equity | 60.586 | 69.088 | 76.638 | 82.821 | 90.852 |
Total Common Shares Outstanding | 21.3578 | 21.3578 | 21.3166 | 21.2847 | 21.0559 |
Long Term Investments | 4.628 | ||||
Preferred Stock - Non Redeemable, Net | 0 | 0 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
净收入/起跑线 | -35.821 | -27.531 | -37.037 | -28.378 |
经营活动产生的现金 | -31.5 | -32.064 | -31.215 | -28.216 |
经营活动产生的现金 | 0.519 | 0.395 | 0.303 | 0.175 |
非现金物品 | 5.433 | -0.369 | 0.598 | 0.366 |
营运资金的变化 | -1.631 | -4.559 | 4.921 | -0.379 |
投资活动产生的现金 | 10.751 | -42.56 | -20.62 | -1.461 |
资本支出 | -0.488 | -1.023 | -0.605 | -1.461 |
其他投资现金流量项目,总计 | 11.239 | -41.537 | -20.015 | 0 |
融资活动产生的现金 | 0.695 | 92.172 | 54.871 | 42.019 |
融资现金流项目 | 0 | -4.16 | -0.045 | 0 |
股票的发行(报废),净额 | 0.695 | 96.332 | 54.916 | 42.019 |
现金净变化 | -20.054 | 17.548 | 3.036 | 12.342 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -10.149 | -35.821 | -27.146 | -19.157 | -11.449 |
Cash From Operating Activities | -6.524 | -31.5 | -22.545 | -17.045 | -9.264 |
Cash From Operating Activities | 0.122 | 0.519 | 0.383 | 0.247 | 0.118 |
Non-Cash Items | 3.81 | 5.433 | 3.946 | 2.508 | 1.169 |
Changes in Working Capital | -0.307 | -1.631 | 0.272 | -0.643 | 0.898 |
Cash From Investing Activities | 1.52 | 10.751 | -0.035 | -9.096 | -13.657 |
Capital Expenditures | 0 | -0.488 | -0.484 | -0.304 | -0.136 |
Other Investing Cash Flow Items, Total | 1.52 | 11.239 | 0.449 | -8.792 | -13.521 |
Cash From Financing Activities | 0 | 0.695 | 0.614 | 0.587 | 0.092 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 0 | 0.695 | 0.614 | 0.587 | 0.092 |
Net Change in Cash | -5.004 | -20.054 | -21.966 | -25.554 | -22.829 |
交易計算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Graybug Vision, Inc. Company profile
关于 Graybug Vision Inc.
Graybug Vision, Inc.是一家临床阶段的生物制药公司,致力于开发治疗视网膜和视神经疾病的变革性药物。 公司的主要候选产品GB-102是一种玻璃体内注射舒尼替尼的微粒子制剂,舒尼替尼是一种新生血管生长和渗透性的抑制剂,而新生血管生长和渗透性是导致视网膜疾病的原因。 该公司正在开发GB-102,作为每六个月一次的玻璃体内注射,用于治疗湿性年龄相关性黄斑变性或湿性(AMD)和糖尿病黄斑水肿(DME)。 该公司还在利用其技术开发GB-103,一种一年一次的GB-102制剂,用于治疗糖尿病视网膜病变(DR),以及GB-401,一种玻璃体内注射的β-肾上腺素能阻断剂原药制剂,用药方案为每六个月一次或更长,用于治疗原发性开角型青光眼(POAG)。
Industry: | Bio Therapeutic Drugs |
274 Redwood Shores Parkway
P.O. Box 144
REDWOOD CITY
CALIFORNIA 94065
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球500,000万多名交易者的一份子,选择利用Capital.com进行交易吧。